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Abstract 
The PAMELA (Particle Accelerator for MEdical 
Applications) project is to design an accelerator for 
proton and light ion therapy using non-scaling Fixed 
Field Alternating Gradient (ns-FFAG) accelerators, as 
part of the CONFORM project, which is also 
constructing the EMMA electron model of a non-
scaling FFAG at Daresbury. This paper presents an 
overview of the PAMELA design, and a discussion of 
the design goals and the principles used to arrive at a 
preliminary specification of the accelerator. 
INTRODUCTION 
Charged Particle Therapy (CPT) [1] uses protons and 
light ions (for example, carbon) to treat some cancers. 
After being proposed [2] by R.R. Wilson in 1946, the 
first patients were treated with protons in Berkeley in 
1954. CPT has now moved out of the laboratory and 
into the hospital, and there are now 29 facilities world-
wide in operation with several more under construction. 
Over 70,000 patients [3] have been treated so far. 
Existing facilities use cyclotrons or synchrotrons to 
accelerate the charged particles. However, it is possible 
that improved performance could be achieved through 
the use of non-scaling FFAG accelerators, leading to 
faster energy variation and spot-scanning capability, 
contributing to a better patient experience, shorter 
treatment times and lower overall cost. 
CLINICAL REQUREMENTS 
The advantages of charged particle therapy over 
conventional radiotherapy using MV X-rays can be 
seen from Figure 1. At a single proton energy setting, a 
high dose can be delivered to the tumour while 
delivering a low dose to the healthy tissue on entry, and 
no dose on exit, whereas a single X-ray beam delivers a 
higher dose to the healthy tissue on entry, and a 
significant dose on exit. Of course, in conventional X-
ray therapy, a lethal dose is delivered to the tumour 
while delivering a much lower dose to healthy tissue by 
irradiating the tumour from many directions. However, 
this has the effect of exposing a large volume of 
healthy tissue to radiation, including some potentially 
radio-sensitive organs. Using the same technique with 
protons results in a very significant reduction (between 
one half and one tenth typically) in the volume of 
healthy tissue irradiated, and/or a significant reduction 
in the dose received by healthy tissue.  Light ions have 
a higher Relative Biological Effectiveness (RBE) – for 
carbon this is typically 3-5 – leading to an even larger 
ratio between the peak and the entry dose, but with a 
small fragmentation dose behind the tumour.  
 
Figure 1: The % energy deposition as function of 
depth for protons and photons, showing the Bragg 
peak (the “pristine” peak), and the Spread-out Bragg 
Peak (SOBP). (from [1]). 
For large tumours, the full tumour volume can be 
irradiated uniformly by varying the energy, so that the 
accumulation of the Bragg peaks takes account of the 
energy deposited in the tumour before the Bragg peak 
for the higher energy positions. As can be seen from 
Figure 1, the dose per volume element (voxel) has a 
large dynamic range (for a 10 cm tumour, this is about 
20). The dose delivered to the tumour must be within 
2% of the planned value. 
A partial set of requirements on the accelerator 
capabilities for a clinical therapy system is shown in 
Table 1. The potential advantages of FFAG 
accelerators over cyclotrons and synchrotrons are that 
in principle they should be able to extract the beam at 
variable energy and at a high (~kHz) repetition rate, 
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ions relatively quickly, and to be able to match 
cyclotrons and synchrotrons in terms of dose rate, dose 
stability and dose precision. 
 
Table 1: A summary of the main clinical requirements 
on the accelerator for a Charged Particle Therapy 
centre with both protons and carbon ions. 
 
Parameter  Value 
Extraction energy (proton) 
[Min, Max] 
[MeV] 60, 250 
Extraction energy (carbon) 
[Min, Max] 
[MeV/u] 110, 450 
Energy step (proton)   
[@Min, @Max] 
[MeV] 5, 1  
Energy step (carbon)    
[@Min, @Max] 
[MeV/u] 15, 6 
Energy resolution  (FWHM)   
[@Min, @Max] 
[%]  3.5, 1.8 
Voxel Size                        
[Min, Max] [mm] 
4×4×4 
10×10×10 
Smallest Field of view      
[Min, Max] [mm] 
100×100 
250×250 
Dose rate (proton)           
[Min, Max] 
[Gy/min] 2, >10 
Dose rate (carbon)        
[Min, Max] 
[Gy/min] 2, >10 
Cycle rate                     
[Min, Max] 
[kHz] ~1 
Bunch charge (proton)     [pC] 1.6 
Bunch charge (carbon)      [pC] 0.3 
Bunch charge stability  [%] <10 
PAMELA 
The ns-FFAG was invented in 1999 [4]. In their 
original incarnation, the magnetic design was arranged 
to greatly compress the range of orbit radii and thus the 
magnet aperture, while maintaining a linear magnetic 
field, leading to expectations of smaller apertures, and 
thus significant cost reduction when compared with 
scaling machines. EMMA, the Electron Model with 
Many Applications will demonstrate the feasibility of 
this technology, and is described elsewhere [5]. Briefly, 
EMMA is a 42-cell, densely-packed ring, with the 
linear magnetic fields provided by displaced 
quadrupoles, and achieving  rapid acceleration by using 
19 1.3GHz cavities, each with an accelerating voltage 
of 20-120kV, giving an energy gain per turn of between 
0.38 MeV and 1.28 MeV. 
While this lattice is a natural starting point for 
PAMELA, there are features that make it unsuitable for 
protons and light ions. Studies with a 48-cell densely 
packed linear lattice showed that it was difficult to 
achieve the high packing fraction with a realistic 
magnet design, and there was insufficient space in the 
short straight sections for the variable frequency RF 
cavities needed for the non-relativistic acceleration. It 
was also shown that the requirements on the field 
accuracy and alignment precision were severe. 
An alternative is to study a less dense lattice with 
longer straight sections, which means departing from 
simple linear magnetic fields. An advantage of this 
approach is that it is then possible to stabilise the 
horizontal and vertical tune (to avoid resonance 
crossing) and to limit the orbit excursion. There are 
several ways to achieve this. One approach [6] uses 
both edge and alternating gradient focussing to stabilise 
the tune. An alternative approach [7] is to stabilise the 
tunes through the addition of higher-order multipoles. 
One such lattice is shown in Figure 2. 
 
Figure 2: A tune-stabilized non-linear non-scaling 
FFAG lattice for protons 31 MeV to 250 MeV. 
The lattice has 12 triplet (FDF) cells, with a median 
radius of 6.25m and 1.95m long straight sections (about 
1.7m of useful length) see Table 2. 
Table 2: Lattice Parameters 
 Injec-
tion 
Refer-
ence 
Extrac-
tion 
Proton K.E.    [MeV] 31 118 250 
C6+ K.E       [MeV/u] 7.8 31 68.4 
Bρ             [Tm] 0.81 1.62 2.43 
# Cells, R0           [m] 12, 6.25 
K value, D/F ratio 38, 1.35 
BD0, BF0               [T] 2.25, 1.67 
Packing factor 0.48 
Long, Short drift [m] 1.7, 0.31 
Magnet length     [m] 0.31 
Orbit excursion   [m] 0.17 
The performance of this lattice is discussed in [8]. 
Preliminary ideas for the design of the magnets [9] and 
the RF [10] have been developed. The field shapes for 
the main ring magnets [9] are shown in Figure 3. An 
outline of the RF cavity from reference [10] is shown in 
Figure 4, with the principal parameters in Table 3. 
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 Figure 3: Magnetic field as a function of radius for 
the F and D magnets. 
 
Figure 4: PAMELA RF cavity 
Table 3: RF Cavity Parameters 
Frequency [h=10] injection [MHz] 19.4 
Frequency [h=10] extraction (max) [MHz] 46.2 
Repetition Rate   [kHz] 1 
Energy gain/turn   [keV] 100 
Number of cavities ≤ 8 
Length    [mm] 1100 
Aperture   [mm] 230 
There are also preliminary ideas ([11]-[12]) for the 
injection chain (see Figure 5). The protons and carbon 
ions will be produced in separate sources, allowing 
faster switching between ion species in a clinical 
situation, improving the productivity of the facility. A 
Low Energy Beam Transport line (LEBT) will 
transport the particles from the sources into a pre-
accelerator, and another beam transport section 
(MEBT) will inject the particles into PAMELA. A 
standard 30MeV proton cyclotron can be used for the 
proton beam injection, and a radio frequency 
quadrupole (RFQ) and linac can be designed for the 
carbon injection.  
Finally, in order to achieve the performance 
requirements in the treatment room, it is necessary to 
use an achromatic beam transport and gantry. Studies 
are under way [12] to design an FFAG-like beam 
transport system. 
  
 
Figure 5: Schematic of proposed injector assembly, 
including ion sources, LEBT, pre-accelerators and 
MEBT. The proton source is contained within the 
cyclotron. 
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